CAMBRIDGE, Mass., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the promotion of Adelene Q. Perkins to president and chief business officer. In this position, Ms. Perkins will continue to have responsibility for all of Infinity's business functions, including corporate and product strategy, business development, finance, organizational development and human resources, investor and public relations, legal, and facilities and operations.
"Adelene's promotion to President acknowledges her outstanding leadership qualities and her passionate commitment to Infinity's mission to discover, develop, and deliver to patients best-in-class medicines," said Steven H. Holtzman, chair and chief executive officer of Infinity. "Adelene's guiding hand over the last six years has been instrumental in building Infinity to its position today."
"Adelene is one of the most skilled business people in this industry," said Dr. Anthony B. Evnin, general partner at Venrock Associates and Infinity's lead outside director. "Adelene has the strategic vision, leadership skills, and operational effectiveness to create value for Infinity and its shareholders."
Ms. Perkins, promoted from the position of executive vice president and chief business officer, has been one of the company's key leaders since joining in 2002. Ms. Perkins came to Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development; she previously held senior leadership positions at Genetics Institute and Bain and Company.
Ms. Perkins is a 2008 finalist to receive a lifetime achievement award from The Stevie(r) Awards for Women in Business.
Ms. Perkins holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from Villanova University. She and her husband, Roland Perkins, have four children.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.